Abstract 185P
Background
It has been proven that with tumor lesions of the organs of the biliopancreatoduodenal (BPDZ), tumor cells excessively release tumor necrosis factor (TNF-α) in the blood serum and determining their level can assess the activity of the tumor process and the effectiveness of the therapy. Among the causes of mechanical jaundice, the pancreatic head tumor prevailed - 36.1% of patients, in 27.7% of patient's cholestasis was due to a liver gate tumor, in 16.6% - a tumor of the terminal segment of the choledochus, in 13.8% - cancer of the Voter papilla, 5.5% - cancer of the common hepatic duct.
Methods
The study involved 32 patients treated at the General Surgery Department in Tashkent Medical Academy with mechanical jaundice (MJ) with malignant etiology after the application of per-cutaneous-transhepatic cholangiostomy (PTCH). The age of patients ranged from 30 to 74 years, averaging 53.7 ± 3.2 years. There were 19 women and 13 men. In order to remove TNF-α from the body, cholesorption was performed.
Results
The initial concentration of TNF-α in serum averaged 467.43 ± 12.36 (in the norm of 0-5.9 pg/ml). The use of cholesorption contributed to a sharp decrease in the concentration of TNF-α in serum and enhancement of its elimination from the bile. On the 3rd day of observation in the serum, there was a decrease in the concentration of TNF-α by 55.7%. The following days, the serum TNF-α concentration tended to increase and on the 6th day, it averaged 242.05 ± 15.6pg / ml. The next day, serum levels showed a gradual decrease in the concentration of TNF-α and on the 10th day of cholesorption averaged 89.46 ± 7.4-65.49 ± 8.95pg / ml, respectively. On the 14th day of cholesorption in comparison with the initial level, the concentration of TNF-α in the serum decreased 5.5 times.
Conclusions
Thus, the use of cholesorption in patients with MJ of tumor genesis contributes to ridding the body of the pro-inflammatory cytokine TNF-α. The determination of TNF-α in the bile increases the objectivity of the method in assessing the course of the main process and the treatment carried out for BPDZ tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract